Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023

SELL
$2.67 - $3.86 $2 - $3
-1 Reduced 0.8%
124 $0
Q4 2022

Feb 14, 2023

SELL
$1.9 - $3.73 $98 - $193
-52 Reduced 29.38%
125 $0
Q3 2022

Nov 14, 2022

BUY
$2.0 - $3.2 $354 - $566
177 New
177 $0

Others Institutions Holding IPHA

About Innate Pharma SA


  • Ticker IPHA
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 79,893,000
  • Market Cap $141M
  • Description
  • Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and periphera...
More about IPHA
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.